A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors
A Phase 1 First-In-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Activity of FP008 in Subjects With Advanced Solid Tumors
Zhuhai Fapon Biopharma Co., Ltd.
108 participants
Jun 12, 2025
INTERVENTIONAL
Conditions
Summary
The goal of the phase 1 study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics activity of FP008 in subjects with advanced solid tumors.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
FP008 should be administered intravenous weekly. Six FP008 dose levels are planned to evaluated.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06990698